PainChek Limited (ASX:PCK) Expands Implementation and Market Reach
PainChek Limited (ASX:PCK) reports growth in implemented licenses and new government partnerships enhancing market opportunities.
PainChek Limited (ASX:PCK) reports growth in implemented licenses and new government partnerships enhancing market opportunities.
Syntara Limited reports positive interim data from its Phase 2 trial of SNT-5505, indicating potential as a breakthrough treatment for myelofibrosis.
Positive interim data from Syntara Limited’s SNT-5505 trial in myelofibrosis indicates significant clinical potential.
OpenLearning Limited (ASX: OLL) has announced a voluntary suspension of its securities pending a key announcement regarding a related party loan facility.
Immutep Limited (ASX: IMM) has announced the initiation of TACTI-004, a Phase III trial for first-line metastatic non-small cell lung cancer.
Integral Diagnostics receives ACCC clearance for its merger with Capitol Health, expecting implementation by 20 December 2024.
Doctor Care Anywhere announces Laura O’Riordan as new CEO from January 2025, focusing on growth and quality in virtual healthcare.
Integral Diagnostics secures ACCC approval for Capitol Health acquisition, requiring divestiture of a clinic in the Melton region.
Anteris Technologies Ltd (ASX: AVR) launches a U.S. IPO for 14.8 million shares to advance its innovative medical solutions.
LTR Pharma Limited secures A$25 million to advance its SPONTAN® treatment through regulatory processes in the U.S. market.